Jiangsu Hengrui Medicine Co., Ltd.
600276.SS
$-0.04
Change (1 day)
$7.89
Year High
$4.87
Year Low
Categories
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
Earnings for Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)
Earnings in 2023 (TTM): $639.67 M
According to Jiangsu Hengrui Medicine Co., Ltd.'s latest financial reports the company's current earnings (TTM) are $639.67 M. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Jiangsu Hengrui Medicine Co., Ltd.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $639.67 M | $589.69 M |
| 2022 | $543.92 M | $535.41 M |
| 2021 | $612.15 M | $620.91 M |
| 2020 | $945.09 M | $867.37 M |
| 2019 | $830 M | $730.26 M |
| 2018 | $616.64 M | $557.23 M |
| 2017 | $515.23 M | $440.87 M |
| 2016 | $412.99 M | $354.84 M |
| 2015 | $351.14 M | $297.63 M |
| 2014 | $246.66 M | $207.72 M |
| 2013 | $202.65 M | $169.7 M |
| 2012 | $184.55 M | $147.67 M |
| 2011 | $145.97 M | $120.15 M |
| 2010 | $117.9 M | $99.25 M |
| 2009 | $107 M | $91.24 M |
| 2008 | $64.42 M | $57.97 M |
| 2007 | $70.1 M | $56.59 M |
| 2006 | $39.65 M | $28.32 M |
| 2005 | $30.25 M | $22.23 M |
| 2004 | $23.66 M | $16.81 M |
| 2003 | $20.65 M | $12.95 M |
| 2002 | $15.15 M | $10.82 M |
| 2001 | $13.39 M | $11.12 M |
| 2000 | $11.22 M | $8.95 M |
| 1999 | $8.6 M | $7.04 M |
| 1998 | $7.15 M | $5.93 M |
| 1997 | $6.1 M | $5.63 M |